Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Eurofins Ntd Llc |
RCV000733894 | SCV000861998 | uncertain significance | not provided | 2018-06-21 | criteria provided, single submitter | clinical testing | |
| Illumina Laboratory Services, |
RCV001156654 | SCV001318168 | uncertain significance | Alpha-methylacyl-CoA racemase deficiency | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
| Labcorp Genetics |
RCV001156654 | SCV002206266 | uncertain significance | Alpha-methylacyl-CoA racemase deficiency | 2022-06-27 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 171 of the AMACR protein (p.Arg171Cys). This variant is present in population databases (rs773780945, gnomAD 0.008%). This variant has not been reported in the literature in individuals affected with AMACR-related conditions. ClinVar contains an entry for this variant (Variation ID: 597697). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Center for Precision Genome Editing and Genetic Technologies for Biomedicine, |
RCV005055134 | SCV005688966 | uncertain significance | Congenital bile acid synthesis defect 4 | 2024-07-01 | criteria provided, single submitter | clinical testing | AMACR(NM_014324.6):c.511C>T (p.Arg171Cys) This variant has been detected in control samples with an allele frequency of 0,00004957 and has not been detected in patients Bile acid synthesis defect, congenital, 4 (OMIM: 214950), so the PM2 criterion applies. BayesDel addAF and BayesDel no AF programs are considered a pathogenic option, PP3 criterion. Based on the applied ACMG/AMP criteria (PM2, PP3), this variant meets the classification for VUS in Bile acid synthesis defect, congenital, 4. |